The authors report the case of a 70-year-old man with metastatic colon cancer and no known history of coronary disease or major risk factors who developed coronary vasospasm after the initiation of capecitabine (Xeloda®). Although coronary vasospasm has been associated with another older fluoropyrimidine compound, 5-fluorouracil, this is the first reported occurrence with this relatively newer cancer drug.
Get full access to this article
View all access options for this article.
References
1.
Brito RA, Medgyesy D., Zukowski TH, et al: Fluoropyrimidines: A critical evaluation. Oncology57(suppl 1):2-8, 1999.
2.
Cassidy J.Xeloda® in colorectal cancer. Int J Clin Pract55:326-328, 2001.
3.
www.rocheusa.com/products/xeloda/pi-only.htm
4.
Cassidy J.: Potential of Xeloda® in colorectal cancer and other solid tumors . Oncology57(suppl 1):27-32, 1999.
5.
Van Cutsem E. , Twelves C., Cassidy J., et al, for the Xeloda Colorectal Cancer Study Group: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer : Results of a large phase III studyJ Clin Oncol19:4097-4106, 2001.
6.
Blum JL: Xeloda® in the treatment of metastatic breast cancer. Oncology57(suppl 1):16-20, 1999.
7.
Kleiman NS, Lehane DE, Geyer CE, et al: Prinzmetal's angina during 5-fluorouracil chemotherapy. Am J Med82:566-568, 1987.
8.
Luwaert RJ, Descamps O., Majois F., et al: Coronary artery spasm induced by 5-fluorouracil. Eur Heart J12:468-470, 1991.
9.
Stefenelli T. , Zielinski CC, Mayr H., et al:Prinzmetal's angina during cyclophosphamide therapy. Eur Heart J9:1155-1157, 1988 .
10.
Aisner J., Van Echo DA, Whitacre M., et al: A phase I trial of continuous infusion VP-16-213 (etoposide)Cancer Chemother Pharmacol7:157-160, 1982.
11.
Doll DC, List AF, Greco A., et al: Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med105:48-51, 1986.
12.
La Bianca R. , Beretta G., Cierici M., et al: Cardiac toxicity of 5-fluorouracil: a study of 1083 patients. Tumori68:505-510, 1982.
13.
Allen A.: The cardiotoxicity of chemotherapeutic drugsSemin Oncol19:529-542, 1992.
14.
Rezkalla S. , Kloner R., Ensley J., et al: Continuous ambulatory ECG monitoring during fluorouracil therapy : A prospective study. J Clin Oncol7:509-514, 1989.
Mosseri M., Fingert HJ, Varticovski L., et al : In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res53:3028-3033, 1993.
